Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia

被引:103
作者
Jacoby, Elad [1 ,2 ]
Bielorai, Bella [1 ,2 ]
Avigdor, Abraham [2 ,3 ]
Itzhaki, Orit [3 ,4 ]
Hutt, Daphna [1 ]
Nussboim, Vered [1 ]
Meir, Amilia [1 ]
Kubi, Adva [4 ]
Levy, Michal [4 ]
Zikich, Dragoslav [4 ]
Zeltzer, Li-at [4 ]
Brezinger, Karin [4 ]
Schachter, Jacob [4 ]
Nagler, Arnon [2 ,3 ]
Besser, Michal J. [4 ,5 ]
Toren, Amos [1 ,2 ]
机构
[1] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Div Pediat Hematol & Oncol, Tel Hashomer, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Tel Hashomer, Israel
[4] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, Tel Hashomer, Israel
[5] Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel
关键词
B-CELL; BLINATUMOMAB; CHILDREN;
D O I
10.1002/ajh.25274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autologous CD19 chimeric-antigen receptor (CAR) T cells demonstrated remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (R/R ALL). Here, we report results from a phase 1b/2 study of in-house produced CD19 CAR with a CD28 costimulatory domain. Twenty-one patients with R/R ALL were enrolled, and 20 infused. The median age was 11 years (range, 5-48). Patients had a median of 4 prior regimens, including blinatumomab in 6 and prior stem-cell transplantation in 10. In total 8 patients had extramedullary (EM) leukemic involvement, and prior to lymphodepletion and CAR 7 had active lesions, a group underrepresented in previous trials. In vivo expansion of CAR T cells was observed in 18 patients. In total 16 patients developed cytokine release syndrome, and 11 patients developed neurotoxicity, with no toxic deaths. All responding patients were referred to an allogeneic hematopoietic stem-cell transplantation. The remission rate was 90%, including resolution of all refractory EM sites. Four responding patients relapsed, 3 who had a PCR-MRD positive remission at 28 days following CAR-T cells and 1 patient 21 months after an MRD-negative response. The estimated 1-year event-free survival and overall survival are 73% and 90%, respectively. Patients with R/R EM ALL may also benefit from CAR-T cell therapy.
引用
收藏
页码:1485 / 1492
页数:8
相关论文
共 26 条
[1]   Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia [J].
Aldoss, Ibrahim ;
Song, Joo ;
Stiller, Tracey ;
Nguyen, Tina ;
Palmer, Joycelynne ;
O'Donnell, Margaret ;
Stein, Anthony S. ;
Marcucci, Guido ;
Forman, Stephen ;
Pullarkat, Vinod .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) :858-865
[2]   Relapsed childhood acute lymphoblastic leukaemia [J].
Bhojwani, Deepa ;
Pui, Ching-Hon .
LANCET ONCOLOGY, 2013, 14 (06) :E205-E217
[3]   Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].
Davila, Marco L. ;
Riviere, Isabelle ;
Wang, Xiuyan ;
Bartido, Shirley ;
Park, Jae ;
Curran, Kevin ;
Chung, Stephen S. ;
Stefanski, Jolanta ;
Borquez-Ojeda, Oriana ;
Olszewska, Malgorzata ;
Qu, Jinrong ;
Wasielewska, Teresa ;
He, Qing ;
Fink, Mitsu ;
Shinglot, Himaly ;
Youssif, Maher ;
Satter, Mark ;
Wang, Yongzeng ;
Hosey, James ;
Quintanilla, Hilda ;
Halton, Elizabeth ;
Bernal, Yvette ;
Bouhassira, Diana C. G. ;
Arcila, Maria E. ;
Gonen, Mithat ;
Roboz, Gail J. ;
Maslak, Peter ;
Douer, Dan ;
Frattini, Mark G. ;
Giralt, Sergio ;
Sadelain, Michel ;
Brentjens, Renier .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
[4]   Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults [J].
Gardner, Rebecca A. ;
Finney, Olivia ;
Annesley, Colleen ;
Brakke, Hannah ;
Summers, Corinne ;
Leger, Kasey ;
Bleakley, Marie ;
Brown, Christopher ;
Mgebroff, Stephanie ;
Kelly-Spratt, Karen S. ;
Hoglund, Virginia ;
Lindgren, Catherine ;
Oron, Assaf P. ;
Li, Daniel ;
Riddell, Stanley R. ;
Park, Julie R. ;
Jensen, Michael C. .
BLOOD, 2017, 129 (25) :3322-3331
[5]   Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia [J].
Ge, Ling ;
Ye, Fan ;
Mao, Xinliang ;
Chen, Jia ;
Sun, Aining ;
Zhu, Xiaming ;
Qiu, Huiying ;
Jin, Zhengming ;
Miao, Miao ;
Fu, Chengcheng ;
Ma, Xiao ;
Chen, Feng ;
Xue, Shengli ;
Ruan, Changgeng ;
Wu, Depei ;
Tang, Xiaowen .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (07) :1040-1047
[6]  
Gokbuget N, 2017, HAEMATOLOGICA, V102, pe133, DOI [10.3324/ haematol. 2016.150755., DOI 10.3324/HAEMAT0L.2016.150755]
[7]   Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells [J].
Gust, Juliane ;
Hay, Kevin A. ;
Hanafi, Laila-Aicha ;
Li, Daniel ;
Myerson, David ;
Gonzalez-Cuyar, Luis F. ;
Yeung, Cecilia ;
Liles, W. Conrad ;
Wurfel, Mark ;
Lopez, Jose A. ;
Chen, Junmei ;
Chung, Dominic ;
Harju-Baker, Susanna ;
Tzpolat, Tahsin ;
Fink, Kathleen R. ;
Riddell, Stanley R. ;
Maloney, David G. ;
Turtle, Cameron J. .
CANCER DISCOVERY, 2017, 7 (12) :1404-1419
[8]   Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy [J].
Hay, Kevin A. ;
Hanafi, Laila-Aicha ;
Li, Daniel ;
Gust, Juliane ;
Liles, W. Conrad ;
Wurfel, Mark M. ;
Lopez, Jose A. ;
Chen, Junmei ;
Chung, Dominic ;
Harju-Baker, Susanna ;
Cherian, Sindhu ;
Chen, Xueyan ;
Riddell, Stanley R. ;
Maloney, David G. ;
Turtle, Cameron J. .
BLOOD, 2017, 130 (21) :2295-2306
[9]   Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia [J].
Hu, Yongxian ;
Wu, Zhao ;
Luo, Yi ;
Shi, Jimin ;
Yu, Jian ;
Pu, Chengfei ;
Liang, Zuyu ;
Wei, Guoqing ;
Cui, Qu ;
Sun, Jie ;
Jiang, Jing ;
Xie, Jue ;
Tan, Yamin ;
Ni, Wanmao ;
Tu, Jifang ;
Wang, Jinping ;
Jin, Aiyun ;
Zhang, Hao ;
Cai, Zhen ;
Xiao, Lei ;
Huang, He .
CLINICAL CANCER RESEARCH, 2017, 23 (13) :3297-3306
[10]   Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression [J].
Jabbour, Elias ;
Duell, Johannes ;
Yilmaz, Musa ;
Khoury, Joseph D. ;
Ravandi, Farhad ;
Jain, Nitin ;
Einsele, Hermann ;
Garcia-Manero, Guillermo ;
Konopleva, Marina ;
Short, Nicholas J. ;
Thompson, Philip A. ;
Wierda, William ;
Daver, Naval ;
Cortes, Jorge ;
O'brien, Susan ;
Kantarjian, Hagop ;
Topp, Max S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) :371-374